FGFR3 and Miyoshi myopathy: By doing so, we identified a potential therapeutic compound, pheophorbide a (Pa), and demonstrated that it effectively suppresses FGFR3 activity by reducing FGFR3 half-life and its downstream signaling in both FGFR3-overactivated MM cells and chondrocytes.